Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
National

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

LONDON, Sept 21: Wegovy-maker Novo Nordisk's CEO Mike Doustdar will face pressure on Monday to set out his strategy for competing with US rival Eli Lilly and how he plans to boost the company's growth beyond the blockbuster weight-loss drug.

Novo rode a wave of demand after launching Wegovy in 2021 which helped it become Europe's most valuable listed firm in 2023 with a market capitalisation of more than $600 billion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.